Exact Sciences, Ultima Genomics ink supply agreement

By LabPulse.com staff writers

June 21, 2022 -- Exact Sciences and Ultima Genomics on Tuesday announced a long-term supply agreement by which Exact will obtain access to Ultima's next-generation sequencing (NGS) technologies.

Under the terms of the agreement, Ultima will provide access to its NGS products based on a new architecture designed to enable sequencing at lower cost, the firms said.

The companies also plan to develop one or more of Exact Sciences' cancer diagnostic tests using Ultima's sequencing technology.

In conjunction with the agreement, Exact Sciences became an investor in Ultima and joined its ongoing early access program for its high-throughput NGS instrument platform, the UG 100.

Veracyte announces evidence supporting thyroid genomic test
Veracyte said that a new meta-analysis provides evidence that its Afirma Genomic Sequencing Classifier (GSC) can accurately rule out thyroid cancer in...
Thermo Fisher Scientific obtains CE Mark for NGS, Dx workflows
Thermo Fisher Scientific has received a CE-IVD Mark under the In Vitro Diagnostic Medical Devices Directive (IVDD) for its Ion Torrent Reporter Software...
Rady Children’s Institute launches newborn genetic disease screening
Rady Children's Institute for Genomic Medicine (RCIGM) has launched a program that aims to advance newborn screening for treatable genetic diseases through...
FDA issues EUA for Labcorp NGS test to detect SARS-CoV-2 strains
The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization for the Laboratory Corporation of America (Labcorp) VirSeq SARS-CoV-2...
Tempus, Eli Lilly collaborate to expand genomic testing
Tempus said it will collaborate with Eli Lilly to provide broader access to genomic testing to patients with metastatic non-small cell lung cancer (NSCLC).

Copyright © 2022 LabPulse.com

Last Updated mp 6/21/2022 9:07:32 AM